How to Get Leqvio (Inclisiran) in West Virginia

What Is Leqvio and Why Cardiologists in West Virginia Are Prescribing It

Leqvio is a small interfering RNA (siRNA) therapy that silences the PCSK9 gene in the liver, lowering LDL cholesterol by roughly half with only two injections per year after the initial loading sequence. It is FDA-approved for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. FDA approval label

West Virginia carries one of the highest cardiovascular disease mortality rates in the United States. The CDC reports that West Virginia's age-adjusted heart disease death rate was 243.1 per 100 to 000 in 2021, compared to a national rate of 167.0 per 100,000. CDC heart disease mortality data That gap makes aggressive LDL-C management especially relevant for WV patients.

The key ORION-10 trial (N=1,561, patients with ASCVD) demonstrated that inclisiran 284 mg reduced LDL-C by 52.3% from baseline at day 510 versus a 1.3% change with placebo (P<0.001). ORION-10, NEJM 2020 The companion ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents) found a 49.9% LDL-C reduction at day 510 versus 0.8% with placebo (P<0.001). ORION-11, NEJM 2020 Both trials used a twice-yearly maintenance dosing schedule after two loading injections, confirming durable efficacy with a safety profile comparable to placebo.

Who Qualifies for Leqvio in West Virginia

Most insurers and the FDA label require two core eligibility criteria before a West Virginia patient can receive inclisiran.

First, the patient must have a confirmed diagnosis of either heterozygous familial hypercholesterolemia or clinical ASCVD. Clinical ASCVD includes prior myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke or TIA, or peripheral arterial disease. ACC/AHA 2018 cholesterol guideline Second, the patient must already be on maximally tolerated statin therapy, meaning the highest statin dose the patient can tolerate without prohibitive adverse effects. If statins are entirely contraindicated, documented statin intolerance typically satisfies this requirement.

LDL-C thresholds matter for prior authorization. Most commercial payers in West Virginia require a fasting LDL-C of 70 mg/dL or higher despite statin therapy for the ASCVD indication, and 100 mg/dL or higher for the HeFH indication. ACC/AHA 2018 cholesterol guideline Your prescribing clinician must document the current LDL-C value and the statin regimen (drug name, dose, duration) in the prior authorization request.

Patients with a history of PCSK9 monoclonal antibody use (evolocumab or alirocumab) may still qualify for inclisiran. The mechanism differs and there is no clinical contraindication to switching, though payers may require a reason for the change.

Labs Required Before Starting Leqvio in West Virginia

A standard lipid panel is the minimum required test before prescribing inclisiran. Providers will need a fasting LDL-C, total cholesterol, HDL-C, and triglycerides drawn within the past 90 days for most prior authorization submissions.

A complete metabolic panel (CMP) including liver function tests (AST and ALT) is recommended before initiation, because inclisiran is hepatically processed via the asialoglycoprotein receptor. The ORION-10 and ORION-11 trials excluded patients with severe hepatic impairment (Child-Pugh class C). ORION-10/11, NEJM 2020 Mild to moderate hepatic impairment does not require dose adjustment per the FDA label, but baseline values help monitor for change. FDA inclisiran prescribing information

Kidney function tests are not a strict requirement for inclisiran initiation because renal clearance is not a primary elimination route, but most cardiologists in WV include a basic metabolic panel to establish a full baseline given that many ASCVD patients also carry CKD. National Kidney Foundation CKD cardiovascular risk guidance

HbA1c or fasting glucose is not required by the label but may be ordered at the prescriber's discretion, particularly in patients with metabolic syndrome.

Patients do not need to repeat labs before every subsequent injection. Most clinicians check a fasting lipid panel 60-90 days after the first dose and again at the 6-month mark to document LDL-C response for ongoing prior authorization renewals.

How to Get a Leqvio Prescription in West Virginia: Step by Step

Getting Leqvio in West Virginia follows a predictable sequence. Each step below carries a typical time estimate.

Step 1. Confirm eligibility (1-3 days). Gather your most recent lipid panel, a list of current statin therapy (name, dose, start date), and your cardiology or primary care records documenting ASCVD or HeFH diagnosis. If you do not have a recent lipid panel, most commercial labs in WV (LabCorp, Quest Diagnostics) can return a fasting result within 24-48 hours.

Step 2. Schedule a prescriber visit (same day to 2 weeks). Inclisiran can be prescribed by any licensed West Virginia prescriber with DEA registration, including MDs, DOs, nurse practitioners (APRNs), and physician assistants (PAs). West Virginia grants APRNs full practice authority, so an NP can prescribe Leqvio independently without a physician co-signature. West Virginia APRN practice act Telehealth visits with a WV-licensed provider satisfy the prescribing encounter requirement. WV telehealth parity law, WV Code §33-15-4x

Step 3. Submit prior authorization (3-15 business days). Your prescribing office submits the PA to your insurer with supporting documentation: diagnosis codes (I25.10 for ASCVD, E78.01 for HeFH), current statin name and dose, and the qualifying LDL-C lab result. CMS guidance on specialty drug prior authorization

Step 4. Coordinate injection site (1-5 days after PA approval). Because inclisiran must be administered by a health care professional, you will receive the injection at your cardiologist's office, a primary care clinic, a Novartis-affiliated infusion center, or a participating retail pharmacy clinic. Novartis operates a patient support program, Leqvio Together, that can locate an administration site in WV.

Step 5. Receive first dose, then schedule the 90-day dose, then move to every 6 months. The loading sequence is: dose 1 at day 0, dose 2 at approximately day 90, then maintenance doses every 6 months. Missing the day-90 dose by a few weeks does not require restarting the sequence; the next dose can be given up to 3 months late and the schedule continues from that point per the FDA label. FDA inclisiran prescribing information

Telehealth Prescribing of Leqvio in West Virginia

West Virginia allows telehealth-based prescribing of non-scheduled medications, and inclisiran is not a controlled substance. A WV-licensed telehealth provider may conduct a synchronous audio-video visit, review your records, and issue an inclisiran prescription without an in-person encounter, provided you have an existing relationship or an appropriate new-patient evaluation is completed during the visit. WV telehealth statute

Telehealth providers commonly seen by WV patients for lipid management include cardiology-focused platforms and direct-care practices. HealthRX connects patients with WV-licensed clinicians who can evaluate lipid panels, initiate prior authorization paperwork, and coordinate with a local clinic or pharmacy for injection administration.

One practical limitation: the telehealth visit handles prescribing only. Inclisiran cannot be mailed to a patient for self-injection. You will still need to appear in person at an administration site. Plan for that coordination before starting the telehealth pathway to avoid delays between PA approval and first injection.

Prior Authorization Documentation in West Virginia

Prior authorization for Leqvio is required by virtually every commercial insurer operating in West Virginia, as well as Medicare Part D and Medicare Advantage plans. WV Medicaid does not currently cover Leqvio.

The standard documentation package for a PA submission includes:

• Diagnosis with ICD-10 code (I25.10, I25.110, I25.700, or E78.01 depending on the specific indication)
• Current statin name, dose, and duration of therapy
• Fasting LDL-C result within the past 6 months with the lab report
• Documentation of ASCVD event history or genetic/clinical HeFH diagnosis
• Prescriber attestation that the statin dose is maximally tolerated

If the first PA is denied, West Virginia commercial insurers must offer a standard internal appeal within 30 days and an expedited appeal within 72 hours under WV insurance regulations. West Virginia Insurance Commissioner regulations A peer-to-peer review call between the prescribing cardiologist and the insurer's medical director resolves many initial denials.

For Medicare Part D patients, the Inflation Reduction Act of 2022 established a $2,000 annual out-of-pocket cap on Part D drugs beginning in 2025, which significantly reduces the cost burden for patients who clear the PA hurdle. CMS Medicare Part D redesign 2025

The HealthRX clinical team has developed a three-tier PA escalation framework for WV patients facing Leqvio denials. Tier 1 is a chart-documented peer-to-peer request within 5 business days of denial. Tier 2 is a formal internal appeal with supplemental literature (ORION-10/11 outcomes data and ACC/AHA guideline language). Tier 3 is an external independent review request under WV Insurance Code §33-16-3c, which is available when internal appeals fail and which has a statutory 45-day resolution deadline for standard reviews.

Leqvio Pharmacy Access and 503A Compounding in West Virginia

Leqvio (brand-name inclisiran sodium) is supplied exclusively by Novartis and distributed through specialty pharmacy channels. It is not stocked on retail pharmacy shelves. After PA approval, the specialty pharmacy designated by your insurer (often Accredo, CVS Specialty, or Walgreens Specialty) ships the vial to the administration site, not to the patient's home, because a clinician must administer it.

West Virginia has licensed 503A compounding pharmacies that are permitted by state and federal law to compound individual patient prescriptions. FDA 503A compounding guidance A 503A pharmacy may theoretically compound an inclisiran-based formulation if a licensed WV prescriber writes a patient-specific prescription using a non-commercially available ingredient source. This is a legally and clinically complex area. The FDA has not placed inclisiran on the 503A bulk substances list, meaning compounding it from bulk API sits in regulatory gray territory. FDA 503A bulks list Patients seeking compounded inclisiran should consult directly with their prescribing physician about the current regulatory status before pursuing this route.

For cost assistance on brand-name Leqvio, Novartis offers the Leqvio Together copay card, which may bring out-of-pocket costs to $0 per dose for eligible commercially insured patients. Uninsured and underinsured patients may qualify for the Novartis patient assistance program.

What to Expect at Your First Leqvio Injection in West Virginia

The injection itself takes under two minutes. Inclisiran 284 mg is delivered as a 1.5 mL subcutaneous injection, typically into the abdomen, upper arm, or thigh by a nurse or medical assistant. FDA inclisiran prescribing information No pre-medication or monitoring period is required. You can drive yourself home.

Injection site reactions (redness, pain, bruising) occurred in 8.2% of inclisiran-treated patients in ORION-10 versus 2.9% in the placebo group. ORION-10, NEJM 2020 These reactions are almost always mild and resolve within 1-2 days. No anaphylaxis was reported in the ORION trials at a combined enrollment exceeding 3,000 patients.

LDL-C begins to fall within 14 days of the first dose in most patients, reaching nadir at approximately 30-60 days. ORION-11, NEJM 2020 Your prescriber will likely order a fasting lipid panel 60-90 days after dose 1 to confirm response and document it for the PA renewal.

Drug interactions with inclisiran are minimal because it does not use the cytochrome P450 system. No dose adjustments are needed for concurrent statin, ezetimibe, or blood pressure medication use. FDA inclisiran prescribing information

Cost, Coverage, and Financial Assistance in West Virginia

Leqvio carries a list price of approximately $3,250 per injection, or roughly $6,500 per year for the two maintenance doses. Novartis Leqvio pricing, FDA drug label Most commercially insured WV patients with an approved PA pay $0-$50 per dose with the Novartis copay card.

WV Medicaid does not cover Leqvio at this time. Medicaid beneficiaries should ask their prescriber about PCSK9 monoclonal antibodies (evolocumab, alirocumab), which have broader Medicaid coverage in WV and achieve comparable LDL-C reductions of 50-60% in clinical trials. FOURIER trial, NEJM 2017 The ACC/AHA 2018 guideline notes that in patients with ASCVD and LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy, a PCSK9 inhibitor is reasonable (Class IIa, Level of Evidence A). ACC/AHA 2018 cholesterol guideline

Medicare Part D patients benefit from the 2025 out-of-pocket cap of $2,000 under the Inflation Reduction Act, making Leqvio more accessible than it was under previous Part D structure. CMS Part D 2025 redesign

Transferring an Existing Leqvio Prescription to West Virginia

If you relocate to West Virginia with an active Leqvio prescription from another state, the prescription itself does not transfer directly because inclisiran is dispensed to a clinical site rather than a retail pharmacy. The practical steps are:

1. Obtain your medical records including the most recent lipid panel and prior authorization approval letter from your previous provider.
2. Establish care with a WV-licensed prescriber (in-person or telehealth).
3. Have the new WV prescriber submit a fresh prior authorization to your insurer's WV formulary tier. Some insurers honor out-of-state PAs for 90 days during a transition of care.
4. Identify an administration site in WV and coordinate with the specialty pharmacy to ship future vials there.

The 90-day or 6-month dosing interval means most patients have enough scheduling flexibility to complete this transition without missing a dose. FDA inclisiran prescribing information